DePuy Synthes launched the CONDUIT Interbody Platform with EIT Cellular Titanium Technology. The portfolio includes 3D-printed titanium interbody implants with 80% porosity to mimic the 50% to 90% porosity of natural bone.
This is the first series of devices to launch from Johnson & Johnson's 2018 acquisition of Emerging Implant Technologies (EIT). CONDUIT Implants and DePuy Synthes' ACIS ProTi 360° Anterior Cervical Interbody System Hyperlordotic Cages are expected to strengthen the company's interbody cage lineup and contribute to a revenue boost for its spine segment.
CONDUIT implants feature nanoscale surface roughness to support osteoblast adhesion and a modulus of elasticity similar to cancellous bone.
|DePuy Synthes' CONDUIT Interbody Platform with
EIT Cellular Titanium Technology
(Sources: DePuy Synthes; ORTHOWORLD)